Medicine
Zerbaxa 1 g/0.5 g per 10 mL powder for injection
Zerbaxa 1 g/0.5 g per 10 mL powder for injection is a prescription medicine containing Ceftolozane and Tazobactam for intravenous use, marketed by Merck Sharp & Dohme, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Storage after reconstitution and dilution is described elsewhere in the…
Key facts
- Active ingredient (INN)
- Ceftolozane and Tazobactam
- Brand
- Zerbaxa
- Strength
- 1 g/0.5 g per 10 mL
- Dosage form
- Powder for injection
- Route
- Intravenous
- Packs
- 10 vials
- Marketing authorisation holder
- Merck Sharp & Dohme
- Manufacturer
- Merck Sharp & Dohme
- Origin register
- US FDA, United States
- Storage
- Storage after reconstitution and dilution is described elsewhere in the labeling.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J01DI54 Ceftolozane and Tazobactam
- HS code (indicative)
- 3004.20Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 19 December 2014
- Identifiers
- RxCUI 1597615, 1597620DailyMed set ID 70ac1d90-eff3-4f0b-9f46-5846c571b32fNDC 67919-030Application NDA206829
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 10 vial, single-dose in 1 carton / 10 mL in 1 vial, single-dose | 67919-030-01 | Merck Sharp & Dohme | 19 December 2014 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Ceftolozane and Tazobactam is a fixed-dose combination of a cephalosporin antibacterial and a beta lactamase inhibitor indicated for the treatment of infections caused by designated susceptible microorganisms in adult, among other approved uses. MedsAcross supplies Ceftolozane and Tazobactam for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Ceftolozane and TazobactamFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- ZERBAXA prescribing information (Merck Sharp & Dohme) · U.S. National Library of Medicine, DailyMed
- Zerbaxa: European public assessment report (EPAR) · European Medicines Agency
Need Zerbaxa 1 g/0.5 g per 10 mL powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.